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Abstract PIAS3, a member of the protein inhibitor of acti-
vated STAT family, was found to interact in vivo and in vitro
with TIF2, a previously described coactivator for nuclear recep-
tors. The interaction is mediated by two distinct non-contiguous
regions of TIF2. We found that TIF2^PIAS3 interaction occurs
through a unique domain of PIAS3, very rich in acidic residues
and conserved throughout the PIAS family. PIAS3 modulates
the ability of TIF2 to mediate ligand-enhanced transcription
activation positively or negatively, for di¡erent steroid recep-
tors. Taken together, our results indicate a potential role
of PIAS3 as transcriptional modulator of TIF2-mediated
signalling. & 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Nuclear receptors (NRs) comprise a family of transcription
factors that regulate gene expression in a ligand-dependent
manner. The NR superfamily includes receptors for steroid
and thyroid hormones, retinoids, vitamin D, as well as recep-
tors for fatty acids, prostaglandins and intracellular metabo-
lites [1,2]. NRs can activate or repress target genes by binding
to cognate DNA response elements as homo- or heterodimers.
Ligand binding induces a transconformation of helix H12, a
short amphipathic helix in the carboxy-terminus of the NR
ligand binding domain, which in the agonist conformation
contributes to the surface required for the interaction with
transcriptional coactivators. Helix H12 is thus an integral
part of the transcription activation function 2 (AF2) that is
induced by agonists [3]. Concomitantly with agonist binding
the interface established between co-repressors and some hor-
mone-free NRs is destabilized. Binding of coactivators and
co-repressors to the NRs results in the assembly of distinct
multiprotein complexes which exert, respectively, histone ace-
tyltransferase (HAT) and histone deacetylase (HDAC) activ-
ity. It is believed that acetylation of histone tails results in
decondensation of chromatin which may be a prerequisite,
or is su⁄cient, for transcriptional activation by agonist-bound
NRs. Acetylation and deacetylation of non-histone proteins
and other transcription factors have been reported to be medi-
ated by the HAT and HDAC complexes, but the signi¢cance
of these events in the context of NR signalling has remained
elusive. In addition to HAT and HDAC complexes, other
multiprotein complexes such SWI/SNF and TRAP/SMCC/
DRIP/ARC complexes have been shown to be involved in
NR signalling. The precise temporal order of action and de-
tailed implication of these various complexes are still not well
understood (see for review [4^8]).
Members of the p160 coactivators, such as human SRC-1,
TIF2 and AIB1, contain two di¡erent transcription activation
domains (AD1 and AD2) in the carboxy-terminus. AD1 acts
through recruitment of the CREB binding protein (CBP) or
the CBP-related protein p300 [9]. Additional factors, some of
which exhibit methyltransferase enzymatic activity, can be re-
cruited to the AD2 of p160 coactivators [10^12]. The p160
family of nuclear receptor coactivators contains a highly con-
served amino-terminal basic helix-loop-helix (bHLH)/PAS do-
main that is also present in members of the Per/Arnt/Sim
(PAS) family of transcription factors and mediates protein^
protein interactions. The role of this putative protein dimeri-
zation motif in the context of the p160 family factor remains
to be established.
In mammals, PIAS proteins were ¢rst discovered as tran-
scriptional co-regulators of the JAK-STAT pathway [13]. The
binding of cytokines to cell surface receptors activates the
Janus family of tyrosines kinases (JAK), which phosphorylate
a family of at least seven cytoplasmic transcription factors
termed STAT (signal transducer and activator of transcrip-
tion). PIAS1 (protein inhibitor of activated STAT-1) was
identi¢ed as a speci¢c inhibitor of STAT-1 signalling, but
conversely can enhance the transcriptional activity of steroid
hormone receptors [13^15]. In vertebrates, ¢ve PIAS proteins
(PIAS1/GBP, PIAS3, ARIP3/PIASxK, Miz/PIASxL and
PIASy) are known [13,14,16]. All PIAS proteins have been
reported to coactivate certain steroid receptor-dependent tran-
scriptions. This e¡ect varied depending on the steroid recep-
tor, the promoter, and the cell type studied [13,14,16,17].
PIAS1 and PIAS3 inhibit DNA binding of the STAT-1 and
STAT-3 factors [13,18]. In contrast, the PIASy protein re-
presses the transcriptional activity of STAT-1 and the andro-
gen receptor without a¡ecting their DNA binding ability [15].
In Drosophila, the PIAS ortholog dPIAS cooperates with
stat92E to regulate eye and blood cell development, presum-
ably by transcriptional regulation [19]. However, an even
more general role for PIAS family protein was suggested by
the characterization of the suppressor of position e¡ect vari-
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egation, Su(var)2^10 (or ZIMP), as a Drosophila PIAS [20].
De¢ciencies in Su(var)2^10 caused strong e¡ects on both mi-
totic chromosome condensation and the organization of inter-
phase chromatin. In this regard, it has recently been reported
that PIASy regulates the activity and subnuclear localization
of the Wnt-responsive transcription factor LEF1 by directing
SUMO (small ubiquitin-related modi¢er) addition to LEF1
[21]. Notably, PIASy binds to nuclear matrix-associated
DNA sequences and targets LEF-1 to nuclear bodies, suggest-
ing that PIASy-mediated subnuclear sequestration accounts
for the repression of LEF1 activity.
To understand the molecular mechanism of TIF2 functions
and identify potential associated proteins, we performed a
yeast two-hybrid screen using the amino-terminal region of
TIF2, containing the bHLH/PAS domain as bait. We identi-
¢ed PIAS3 as a protein that interacts speci¢cally with TIF2 in
vivo and in vitro.
2. Materials and methods
2.1. Two-hybrid screening
The TIF2 deletion mutant containing amino acids 1^624 was cloned
in phase 3P of the DNA binding domain of LexA in pBTM116 to
produce a bait fusion protein. A mouse embryo (9.5^12.5 dpc) cDNA
library in the VpASV3 phage yeast vector was used for screening [22];
ampli¢cation and plasmid excision (cre-lox system) was done in Es-
cherichia coli BNN132. After plasmid excision cDNAs are expressed
as VP16 acidic activation domain fusions. Two-hybrid screening [23]
was done by sequential transformation of bait and library vectors in
Saccharomyces cerevisiae L40K carrying two genomically integrated
reporters, the lexA-HIS3 and lexA-LacZ. After transformation, yeast
were plated on histidine-lacking selective media containing 30 mM
3-amino-1,2,4-triazole and incubated at 30‡C until transformants ap-
peared. Transformants that grew more rapidly were restreaked in
duplicate in selective medium and tested for L-galactosidase expres-
sion. One clone (N256) was selected for further analysis. Database
searches using the N256 sequence showed that N256 is identical to
the mouse PIAS3.
2.2. Plasmids
All recombinant DNA work was performed according to standard
procedures. VP16-PIAS3 and VP16-N256 were constructed by cloning
a BamHI fragment containing full-length PIAS3 cDNA or the clone
isolated in the two-hybrid screening into the BamHI site of vector
pSG5-NVP16-LB3. pSG5-NVP16-LB3 contains a cassette expressing
a nuclear localized VP16 AAD in the context of the pSG5 vector [24].
VP16-PIAS3v(340^482) was constructed by homologous recombina-
tion. Brie£y, the N-terminal part of PIAS3(1^340) was ampli¢ed by
PCR using the oligos 5P-GTACGGTGGGGGGCTACGGAGATCT-
GCCACCATGGTGATGAGTTTCCGAGTGTCTG-3P (sense) and
AGAAAATAAATCTAAACCTTGTAAACCATCAATAATCAGC-
GACTCATAG-3P (antisense). The oligos 5P-CGCTGATTATTGATG-
GTTTACAAGGTTTAGATTTATTTTCTTTCCTTCAG-3P (sense)
and 5P-AACAAGTTCTGCTTTAATAAGATCTTCAGTCCAGG-
GAAATGATGTCTGAC-3P (antisense) were used to amplify the
C-terminal fragment of PIAS3 (amino acids 482^585). N- and C-ter-
minal fragments of PIAS3 containing homologous sequences for re-
combination in 3P and 5P respectively were used to transform compe-
tent bacteria together with the vector pSG5-NVP16-LB3 linearized at
the BglII site.
The TIF2 cDNA expression vector was previously described [25].
The GAL4-TIF2 chimera was constructed by PCR ampli¢cation of
the full-length cDNA of TIF2 followed by subcloning in PG4MpolyII
[26]. For in vitro binding assays, the indicated regions of TIF2 were
fused to GST in the pGEX-2TK plasmid (Pharmacia) or to a tag of
six histidines in the pCalKc plasmid (Stratagene). The reporter plas-
mid (17m)5-TATA-CAT [27] contains ¢ve copies of the GAL4 re-
sponse element in front of a simple TATA motif upstream of the
CAT reporter gene. Mouse mammary tumor promoter CAT construct
was described previously [28]. Receptor cDNAs used in this study
encode the human glucocorticoid (HG1), androgen (hAR) and pro-
gesterone (hPR1) receptors. Details concerning the plasmid construc-
tions, all of which were veri¢ed by sequencing, are available on re-
quest.
2.3. Pull-down assays with [35S]methionine-labelled proteins
DNA was transcribed and translated in vitro using the TNT T7
coupled reticulocyte lysate system (Promega) following the instruc-
tions of the manufacturer. The reticulocyte lysate containing 35S-la-
belled protein was then incubated as described [29] with puri¢ed
6UHis-tagged or GST-linked TIF2 peptides [30]. Bound proteins
were recovered in SDS sample bu¡er and revealed by £uorography
of SDS^polyacrylamide gels.
2.4. Cell culture and transient transfection
COS-1 cells were maintained in Dulbecco’s minimal essential me-
dium containing penicillin (25 U/ml), streptomycin (25 U/ml), and
10% fetal bovine serum. Transient transfections were performed using
the calcium phosphate co-precipitation protocol in the presence of
phenol red-free medium containing charcoal-treated serum. At 14^
16 h after transfection, COS-1 cells were exposed to dihydrotestoster-
one, dexamethasone, or progesterone for 24 h. Transfected cells were
lysed and assayed for reporter gene activity using the CAT immuno-
detection system (Boehringer Mannheim) according to the manufac-
turer’s instruction. L-Galactosidase, measured as previously described
[9], was used to normalize variations in the transfection e⁄ciencies.
2.5. Immunoblotting
Whole cell extracts of COS-1 cells were prepared in RIPA bu¡er
and resolved by electrophoresis on 12% polyacrylamide gels under
denaturing conditions (SDS^PAGE). Proteins were electroblotted
onto nitrocellulose transfer membrane (Schleicher and Schuell). Mem-
branes were incubated with antibodies against VP16 (IGBMC mono-
clonal antibody service). Horseradish peroxidase-conjugated anti-
mouse immunoglobulin G antibody (Ozyme) was used as the second-
ary antibody. Immunocomplexes were visualized with Western blot-
ting detection reagents according to the manufacturer’s instructions
(Pierce).
3. Results
3.1. Identi¢cation of PIAS3 as an interacting partner for the
nuclear receptor coactivator TIF2 in a yeast two-hybrid
screening
TIF2, a member of the p160 coactivator family, mediates
the transcriptional signalling of nuclear receptors. To gain
further insight into the regulatory mechanisms of TIF2-depen-
dent signalling cascade(s), we searched for additional interac-
tion partners of TIF2. Toward this end, we performed a yeast
two-hybrid screen with a TIF2-LexA fusion protein. The
N-terminal region of hTIF2, TIF2.0, encompassing the ¢rst
640 amino acids of the nuclear receptor coactivator was used
as a bait in a yeast two-hybrid screening of a mouse embryo
cDNA library. Yeast transformants containing the LexA-
DBD fused to the ¢rst 640 amino acids of TIF2 and mouse
proteins fused to the activation domain of VP16 were selected
according to their ability to grow in histidine-lacking media.
The positive transformants were reselected in a second round
for their ability to induce the second reporter gene, lacZ,
present in the yeast strain L40K. Sequence analysis revealed
that one of the positive clones, called N256, encoded a trun-
cated protein of identical sequence to residues 353^546 of
mouse PIAS3.
3.2. TIF2 and PIAS3 interact in mammalian cells
To con¢rm that the TIF2^PIAS3 interaction observed in
yeast cells is relevant in animal cells, we used a mammalian
two-hybrid assay. Indeed, the transcriptional activity of
GAL4 DNA response element-targeted TIF2 (GAL4-TIF2,
comprising the DNA binding domain of GAL and the full-
FEBS 26397 15-8-02
A.M. Jime¤nez-Lara et al./FEBS Letters 526 (2002) 142^146 143
length TIF2) signi¢cantly increased with increasing amount of
vectors that expressed the VP16-tagged N256 or full-length
PIAS3 proteins (Fig. 1B). We thus conclude that PIAS3 is a
novel partner of the TIF2 coactivator.
N256 harbors an acidic region as the sole discernible fea-
ture. As this acidic region is also known to be involved in the
case of PIAS1/STAT-1 interaction, we tested whether it can
also mediate TIF2 binding. For this, we generated a mutant
lacking the characteristic acidic region, PIAS3v340^482, as a
VP16 fusion and we tested its ability to interact with TIF2. In
a mammalian two-hybrid system, this mutant did not retain
the ability of PIAS3 to interact with TIF2 (Fig. 1B). Equal
expression of PIAS3 proteins was con¢rmed by Western blot-
ting (Fig. 1C). These data indicate that a single domain of
PIAS3 that encompasses the acidic region is both necessary
and su⁄cient for the interaction with TIF2
3.3. TIF2 and PIAS3 interact in vitro
To study whether the observed in vivo interaction between
TIF2 and PIAS3 in yeast and mammalian systems is direct or
indirectly mediated by other factors, we performed pull-down
experiments with various immobilized histidine-tagged TIF2
fragments. The originally isolated cDNA clone, N256, encod-
ing the amino acids 353^546 of PIAS3 and the full-length
cDNA of PIAS3 were radiolabelled by in vitro translation,
and their interaction with immobilized His-tagged TIF2 was
determined. Interestingly, fragments of TIF2, TIF2.0 and
TIF2.1, encoding the N-terminal and central part of TIF2
respectively, interacted with both the N256 and the full-length
Fig. 1. Isolation of PIAS3 by two-hybrid screening in yeast. A: A
schematic representation of functional domains of TIF2 as well as
the LexA chimera used as a bait. NID, nuclear receptor interacting
domain; CID, CBP interacting domain; Q rich, glutamic acid-rich
domain. Numbers below the line diagrams indicate the amino acid
positions of the respective protein domains. The VP16 AAD-tagged
mouse embryo cDNA expression library is represented below. Tran-
scription of the integrated HIS3- and lacZ-based reported genes is
regulated by a LexA promoter in the yeast reporter strain L40K.
B: PIAS3 and TIF2 interact in a mammalian two-hybrid system.
Deletion of a region of PIAS3 encompassing the acidic region abol-
ishes the interaction between PIAS3 and TIF2. Schematic line dia-
grams of PIAS3. PIAS3 contains a putative chromatin binding SAP
domain, a RING domain, and a C-terminal acidic domain. COS-1
cells were co-transfected with 300 ng per well of the (17m)5-TATA-
CAT reporter gene, 1 Wg of GAL-TIF2 chimera and increasing
amounts (25, 50, 100 ng) of N256 and (0.25, 0.5, 1 Wg) PIAS3 and
PIAS3v(340^482) VP16 chimeras as indicated. Each bar represents
the mean value obtained from at least three di¡erent experiments,
standard deviations are indicated. In C expression levels of VP16
and VP16-PIAS proteins are shown to demonstrate that they are ex-
pressed at similar levels in transient transfection experiments. COS-1
cells were transiently transfected with expression vectors for VP16,
VP16-N256, VP16-PIAS wild type and VP16-PIAS3v(340^482) in
the same conditions as in two-hybrid assays previously shown. After
24 h of incubation the cells were harvested, and Western blot analy-
sis was performed with anti-VP16 antibody.
Fig. 2. In vitro mapping of PIAS3 interacting domains within TIF2.
A: Schematic line diagrams of TIF2 domains and N- and C-termi-
nally truncated TIF2 proteins used in the assay. B: N256 and
PIAS3 as VP16 chimeras were in vitro translated in the presence of
[35S]methionine and incubated with immobilized puri¢ed GST- or
His-TIF2 fragments in a batch assay. Proteins were resolved by
SDS^PAGE, and detected by £uorography. Lane 1 show 1/5 the
amount of 35S-labelled protein used in the assay.
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PIAS3 protein. However, the C-terminal part of TIF2
(TIF2.2), which contains the activation domain 2 (AD2) did
not interact with these proteins.
To characterize more in detail the observed interaction be-
tween the N-terminal part of TIF2 and PIAS3, we studied the
in vitro interaction between PIAS3 and a fragment encom-
passing the bHLH/PAS domain of TIF2, TIF2.40, using
GST pull-down assays (Fig. 2). The N256 and full-length
PIAS3 proteins e¡ectively bound to this N-terminal region
of TIF2, which spans residues 1^381. Note that no signi¢cant
interaction of PIAS3 was observed in these assays with the
GST part of the fusion proteins. These results indicate that
the bHLH/PAS domain of TIF2 can autonomously interact
with PIAS3. Thus, two non-contiguous regions of TIF2, lo-
cated in the N-terminal (TIF2.0) and in the central (TIF2.1)
regions of TIF2 can independently interact with the region
that encompass the acidic domain of PIAS3.
3.4. TIF2 and PIAS3 di¡erentially coactivate androgen,
glucocorticoids and progesterone receptors
We have demonstrated previously that TIF2 stimulates the
transcriptional activity of several NRs in an agonist- and AF2
integrity-dependent manner. To investigate how PIAS3 could
a¡ect TIF2 transcriptional coactivator activity, reporter gene
assays were performed using the mouse mammary tumor virus
promoter to compare the e¡ect of either PIAS3 or TIF2 alone
or both in combination in the transcriptional regulation medi-
ated by AR (Fig. 3). Coexpression of PIAS3 and AR in-
creased the androgen-dependent transcription activity of the
MMTV promoter, in a similar manner as cotransfection of
TIF2 and AR. Cotransfection of both PIAS3 and TIF2 re-
sulted in an additive enhancement of the androgen response.
We also tested the PIAS3 in£uence on the transcriptional
activation by hGR and hPR. To avoid any di¡erences due
to promoter context, we used the MMTV-CAT reporter. In
contrast to AR-mediated transactivation, coexpression of
PIAS3 inhibited glucocorticoid signalling even though TIF2
enhanced glucocorticoid-mediated transcription. PIAS3 en-
hanced moderately ligand-dependent transactivation by PR,
but it negatively modulated PR function when TIF2 was
present. Thus, PIAS3 behaved in a receptor-selective fashion,
in that its ability to modulate transcription mediated by di¡er-
ent steroid receptors varied substantially.
4. Discussion
The N-terminus is the most highly conserved region in the
TIF2 protein. Nevertheless, no insight into its function has
been obtained so far. The striking homology of the N-termi-
nal region of TIF2 with bHLH/PAS transcription factors sug-
gested to us that the TIF2 N-terminus may establish weak or
non-selective DNA contacts and/or protein^protein interac-
tion to stabilize the coactivator complex(es), help to anchor
the complex to DNA and/or mediate additional protein^pro-
tein interactions required for signalling by the cognate com-
plex. Here, we report the isolation of such an additional in-
teracting partner for TIF2, previously described as mouse
PIAS3.
PIAS proteins share several structural elements well con-
served along all family members. It has recently been pre-
dicted that PIAS proteins harbor a putative DNA binding
domain, the SAP (SAF-A, Acinus, PIAS) module [31], at their
N-termini (residues 1^23 in PIAS3). The C-terminal region of
PIAS3 contains an acidic region (residues 403^418). Deletion
of this region abolished the ability of PIAS3 to interact with
TIF2. This same C-terminal region of PIAS1 has been shown
to be involved in the interaction with STAT-1 and required
for the inhibition of STAT-1-dependent gene activation [32].
The conserved region between amino acids 283 and 325 of
PIAS3 contains a putative RING domain. In this context, it
is of interest to note that recent reports have revealed that an
intact RING domain in PIAS proteins is required for the
ability of these proteins to function as E3-type SUMO-1 li-
gases [33]. Unlike ubiquitylation, sumoylation does not ap-
pear to promote protein degradation but rather was shown
to be involved in establishing protein^protein interactions,
subcellular compartmentalization and protein stability.
Biochemical studies indicate that PIAS proteins interact
directly with di¡erent transcription factors, including STATs,
p53 and steroid receptors, and can regulate their transcrip-
tional activities both positively or negatively [13^15,34]. In
particular, PIAS3 antagonizes the activity of STAT-3, inhib-
iting its DNA binding ability [18], and it can enhance or
inhibit the transcriptional activity of androgen, glucocorti-
Fig. 3. PIAS3 modulates TIF2 transcriptional activity in a nuclear
receptor-dependent manner. COS-1 cells were transfected with 500
ng MMTV-CAT reporter together with 150 ng of androgen (A),
glucocorticoids (B) or progesterone (C) receptors with or without
300 ng of TIF2 and PIAS3 in the presence or absence of the indi-
cated ligands. Each bar represents the mean value obtained from at
least three di¡erent experiments, standard deviations are indicated.
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coid, progesterone and estrogen receptors di¡erently depend-
ing on promoter, steroid receptor and cell type (this study and
[14,15,17]). The mechanism underlying the ability of PIAS
proteins to modulate transcription and, in particular, steroid
receptor-dependent transcription is still unknown. The fact
that PIAS3 was found to interact with TIF2 could suggest a
potential mechanism of PIAS protein actions on nuclear re-
ceptor transcriptional activity through the interaction with
nuclear receptor coactivators. In this regard, it will be inter-
esting to investigate whether sumoylation plays a role in
TIF2/PIAS3/nuclear receptor interaction and/or the function
of its AF(s). Recently, the involvement of ARIP3/PIASxK in
the sumoylation of the mouse homolog of TIF2, GRIP1, was
reported [35^37]. Interestingly, our results demonstrate that
the interaction between TIF2 and PIAS3 involved two surfa-
ces of the TIF2 protein. One of these, encompassing the
bHLH/PAS domain, has been reported to be also involved
in the recruitment of p160 coactivators by TEF-4 transcrip-
tion factors [38]. In contrast to TEF-4, PIAS3 binding can
occur autonomously also through a second interface estab-
lished with the central part of TIF2. This TIF2 region con-
tains the nuclear receptor interacting domain that harbors
three LXXLL motifs and the activation domain 1 or CBP-
interacting domain. No relevant interaction was observed with
the C-terminal part of TIF2 that contains the activation do-
main 2. Further studies will be necessary to determine whether
both PIAS3-interacting domains are required for a functional
interaction between TIF2 and PIAS3, or alternatively, both
domains can interact independently, albeit with di¡erent e⁄-
ciencies, with more than one molecule of PIAS3.
As has been described for other co-regulators of nuclear
receptor coactivators, for example CARM-1 or Zac-1
[10,11], PIAS3 can act together with TIF2 to stimulate andro-
gen-dependent transcription in an additive manner. It has
been reported that PIAS3 can interact physically with AR
[17]. Probably, the triple interaction between PIAS3, AR
and TIF2 could help to stabilize and/or support the activity
of the protein complex. However, it is also possible that the
interactions of PIAS3 with AR and TIF2 in intact cells in-
volve other protein(s) that may be part of a common complex.
On the other hand, PIAS3 inhibits the activity of TIF2 for
glucocorticoid- and progesterone-dependent transcription. As
there is no evidence of direct interaction between PIAS3 and
GR or PR, it is possible that in this case PIAS3 competes with
GR or PR for TIF2 interaction. Di¡erences in the a⁄nities of
NRs and PIAS3 for TIF2 may account for these di¡erent
e¡ects of PIAS3 on TIF2-mediated signalling.
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